Vitamins for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID 19 hospitalized meta-analysis
Murai NCT04449718		RCT	Vitamin D	placebo	COVID 19 hospitalized	some concern	120/120	inconclusive	inconclusive 1 % decrease in hospital discharge (PE) with a moderate degree of certainty due to some concern in risk of bias
COVID-19 mild to moderate meta-analysis
Rastogi NCT04459247		RCT	Vitamin D	placebo	COVID-19 mild to moderate	NA	16/24	suggested	suggested 5.3-fold increase in viral clearance (PE)
COVID-19 severe or critically meta-analysis
Zhang NCT04264533		RCT	vitamin C	placebo	COVID-19 severe or critically	some concern	27/29	inconclusive

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID 19 hospitalized meta-analysis

COVID-19 mild to moderate meta-analysis

COVID-19 severe or critically meta-analysis